PMC:7571312 / 122500-124139 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T7","span":{"begin":55,"end":60},"obj":"Body_part"},{"id":"T8","span":{"begin":83,"end":88},"obj":"Body_part"},{"id":"T9","span":{"begin":274,"end":279},"obj":"Body_part"},{"id":"T10","span":{"begin":454,"end":458},"obj":"Body_part"},{"id":"T11","span":{"begin":553,"end":557},"obj":"Body_part"},{"id":"T12","span":{"begin":630,"end":635},"obj":"Body_part"},{"id":"T13","span":{"begin":737,"end":742},"obj":"Body_part"},{"id":"T14","span":{"begin":765,"end":770},"obj":"Body_part"},{"id":"T15","span":{"begin":1048,"end":1053},"obj":"Body_part"},{"id":"T16","span":{"begin":1115,"end":1120},"obj":"Body_part"},{"id":"T17","span":{"begin":1310,"end":1315},"obj":"Body_part"},{"id":"T18","span":{"begin":1369,"end":1374},"obj":"Body_part"},{"id":"T19","span":{"begin":1569,"end":1574},"obj":"Body_part"},{"id":"T20","span":{"begin":1628,"end":1633},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"All assays were performed in BSL3 containment. Vero 76 cells were plated at 10 000 cells per well using phenol red-free DMEM or IMEM (Gibco). After adhering for 2 h at 37 °C, various concentrations of compound (320, 100, 33, 10, 3.3, 1.0, 0.3, or 0.1 μM) were added and the cells were infected with 2.6 × 103 PFU/well SARS CoV Toronto-2 (provided as a gift from Dr. Heinz Feldman (NIAID, Hamilton, MT)) or mock-infected with the medium only. After 66 h, cell viability was determined using either the neutral red method or the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). For the neutral red method, the cells were washed twice with PBS, and 100 μL of DMEM pH 4.5 containing 0.066% neutral red was added to the cells for 2 h at 37 °C. The cells were again washed twice with PBS, 100 μL of buffer solution (50% EtOH, 1% acetic acid) was added, and the OD was read at 540 nM after a 10 min incubation at 37 °C with shaking. Data are expressed as the percent of neutral red or luminescent signal in wells of compound-treated cells compared to the signal in wells of uninfected, compound-free cells. The 50% effective concentration (EC50) is calculated as the concentration of the compound that increases the percent of the neutral red or luminescent signal in infected, compound-treated cells to 50% of that produced by uninfected, compound-free cells. The 50% cytotoxicity concentration (CC50) is calculated as the concentration of the compound that decreases the percent of the neutral red or luminescent signal in uninfected, compound-treated cells to 50% of that produced in uninfected, compound-free cells.51,52"}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T105","span":{"begin":318,"end":322},"obj":"Disease"},{"id":"T106","span":{"begin":877,"end":879},"obj":"Disease"}],"attributes":[{"id":"A105","pred":"mondo_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A106","pred":"mondo_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/MONDO_0017178"}],"text":"All assays were performed in BSL3 containment. Vero 76 cells were plated at 10 000 cells per well using phenol red-free DMEM or IMEM (Gibco). After adhering for 2 h at 37 °C, various concentrations of compound (320, 100, 33, 10, 3.3, 1.0, 0.3, or 0.1 μM) were added and the cells were infected with 2.6 × 103 PFU/well SARS CoV Toronto-2 (provided as a gift from Dr. Heinz Feldman (NIAID, Hamilton, MT)) or mock-infected with the medium only. After 66 h, cell viability was determined using either the neutral red method or the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). For the neutral red method, the cells were washed twice with PBS, and 100 μL of DMEM pH 4.5 containing 0.066% neutral red was added to the cells for 2 h at 37 °C. The cells were again washed twice with PBS, 100 μL of buffer solution (50% EtOH, 1% acetic acid) was added, and the OD was read at 540 nM after a 10 min incubation at 37 °C with shaking. Data are expressed as the percent of neutral red or luminescent signal in wells of compound-treated cells compared to the signal in wells of uninfected, compound-free cells. The 50% effective concentration (EC50) is calculated as the concentration of the compound that increases the percent of the neutral red or luminescent signal in infected, compound-treated cells to 50% of that produced by uninfected, compound-free cells. The 50% cytotoxicity concentration (CC50) is calculated as the concentration of the compound that decreases the percent of the neutral red or luminescent signal in uninfected, compound-treated cells to 50% of that produced in uninfected, compound-free cells.51,52"}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T116","span":{"begin":47,"end":54},"obj":"http://purl.obolibrary.org/obo/CLO_0009526"},{"id":"T117","span":{"begin":55,"end":60},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T118","span":{"begin":83,"end":88},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T119","span":{"begin":274,"end":279},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T120","span":{"begin":350,"end":351},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T121","span":{"begin":454,"end":458},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T122","span":{"begin":553,"end":557},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T123","span":{"begin":630,"end":635},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T124","span":{"begin":737,"end":742},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T125","span":{"begin":765,"end":770},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T126","span":{"begin":905,"end":909},"obj":"http://purl.obolibrary.org/obo/CLO_0001550"},{"id":"T127","span":{"begin":1012,"end":1018},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T128","span":{"begin":1048,"end":1053},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T129","span":{"begin":1070,"end":1076},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T130","span":{"begin":1115,"end":1120},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T131","span":{"begin":1273,"end":1279},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T132","span":{"begin":1310,"end":1315},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T133","span":{"begin":1369,"end":1374},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T134","span":{"begin":1530,"end":1536},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T135","span":{"begin":1569,"end":1574},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T136","span":{"begin":1628,"end":1633},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"All assays were performed in BSL3 containment. Vero 76 cells were plated at 10 000 cells per well using phenol red-free DMEM or IMEM (Gibco). After adhering for 2 h at 37 °C, various concentrations of compound (320, 100, 33, 10, 3.3, 1.0, 0.3, or 0.1 μM) were added and the cells were infected with 2.6 × 103 PFU/well SARS CoV Toronto-2 (provided as a gift from Dr. Heinz Feldman (NIAID, Hamilton, MT)) or mock-infected with the medium only. After 66 h, cell viability was determined using either the neutral red method or the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). For the neutral red method, the cells were washed twice with PBS, and 100 μL of DMEM pH 4.5 containing 0.066% neutral red was added to the cells for 2 h at 37 °C. The cells were again washed twice with PBS, 100 μL of buffer solution (50% EtOH, 1% acetic acid) was added, and the OD was read at 540 nM after a 10 min incubation at 37 °C with shaking. Data are expressed as the percent of neutral red or luminescent signal in wells of compound-treated cells compared to the signal in wells of uninfected, compound-free cells. The 50% effective concentration (EC50) is calculated as the concentration of the compound that increases the percent of the neutral red or luminescent signal in infected, compound-treated cells to 50% of that produced by uninfected, compound-free cells. The 50% cytotoxicity concentration (CC50) is calculated as the concentration of the compound that decreases the percent of the neutral red or luminescent signal in uninfected, compound-treated cells to 50% of that produced in uninfected, compound-free cells.51,52"}

LitCovid-PD-CHEBI

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T661","span":{"begin":0,"end":46},"obj":"Sentence"},{"id":"T662","span":{"begin":47,"end":141},"obj":"Sentence"},{"id":"T663","span":{"begin":142,"end":441},"obj":"Sentence"},{"id":"T664","span":{"begin":442,"end":597},"obj":"Sentence"},{"id":"T665","span":{"begin":598,"end":760},"obj":"Sentence"},{"id":"T666","span":{"begin":761,"end":947},"obj":"Sentence"},{"id":"T667","span":{"begin":948,"end":1121},"obj":"Sentence"},{"id":"T668","span":{"begin":1122,"end":1375},"obj":"Sentence"},{"id":"T669","span":{"begin":1376,"end":1639},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"All assays were performed in BSL3 containment. Vero 76 cells were plated at 10 000 cells per well using phenol red-free DMEM or IMEM (Gibco). After adhering for 2 h at 37 °C, various concentrations of compound (320, 100, 33, 10, 3.3, 1.0, 0.3, or 0.1 μM) were added and the cells were infected with 2.6 × 103 PFU/well SARS CoV Toronto-2 (provided as a gift from Dr. Heinz Feldman (NIAID, Hamilton, MT)) or mock-infected with the medium only. After 66 h, cell viability was determined using either the neutral red method or the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). For the neutral red method, the cells were washed twice with PBS, and 100 μL of DMEM pH 4.5 containing 0.066% neutral red was added to the cells for 2 h at 37 °C. The cells were again washed twice with PBS, 100 μL of buffer solution (50% EtOH, 1% acetic acid) was added, and the OD was read at 540 nM after a 10 min incubation at 37 °C with shaking. Data are expressed as the percent of neutral red or luminescent signal in wells of compound-treated cells compared to the signal in wells of uninfected, compound-free cells. The 50% effective concentration (EC50) is calculated as the concentration of the compound that increases the percent of the neutral red or luminescent signal in infected, compound-treated cells to 50% of that produced by uninfected, compound-free cells. The 50% cytotoxicity concentration (CC50) is calculated as the concentration of the compound that decreases the percent of the neutral red or luminescent signal in uninfected, compound-treated cells to 50% of that produced in uninfected, compound-free cells.51,52"}

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"2142","span":{"begin":318,"end":326},"obj":"Species"},{"id":"2143","span":{"begin":104,"end":114},"obj":"Chemical"},{"id":"2144","span":{"begin":120,"end":124},"obj":"Chemical"},{"id":"2145","span":{"begin":659,"end":662},"obj":"Chemical"},{"id":"2146","span":{"begin":678,"end":682},"obj":"Chemical"},{"id":"2147","span":{"begin":800,"end":803},"obj":"Chemical"},{"id":"2148","span":{"begin":836,"end":840},"obj":"Chemical"},{"id":"2149","span":{"begin":845,"end":856},"obj":"Chemical"},{"id":"2150","span":{"begin":285,"end":293},"obj":"Disease"},{"id":"2151","span":{"begin":411,"end":419},"obj":"Disease"},{"id":"2152","span":{"begin":1283,"end":1291},"obj":"Disease"},{"id":"2153","span":{"begin":1384,"end":1396},"obj":"Disease"}],"attributes":[{"id":"A2142","pred":"tao:has_database_id","subj":"2142","obj":"Tax:694009"},{"id":"A2143","pred":"tao:has_database_id","subj":"2143","obj":"MESH:D010637"},{"id":"A2145","pred":"tao:has_database_id","subj":"2145","obj":"MESH:D007854"},{"id":"A2147","pred":"tao:has_database_id","subj":"2147","obj":"MESH:D007854"},{"id":"A2148","pred":"tao:has_database_id","subj":"2148","obj":"MESH:D000431"},{"id":"A2149","pred":"tao:has_database_id","subj":"2149","obj":"MESH:D019342"},{"id":"A2150","pred":"tao:has_database_id","subj":"2150","obj":"MESH:D007239"},{"id":"A2151","pred":"tao:has_database_id","subj":"2151","obj":"MESH:D007239"},{"id":"A2152","pred":"tao:has_database_id","subj":"2152","obj":"MESH:D007239"},{"id":"A2153","pred":"tao:has_database_id","subj":"2153","obj":"MESH:D064420"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"All assays were performed in BSL3 containment. Vero 76 cells were plated at 10 000 cells per well using phenol red-free DMEM or IMEM (Gibco). After adhering for 2 h at 37 °C, various concentrations of compound (320, 100, 33, 10, 3.3, 1.0, 0.3, or 0.1 μM) were added and the cells were infected with 2.6 × 103 PFU/well SARS CoV Toronto-2 (provided as a gift from Dr. Heinz Feldman (NIAID, Hamilton, MT)) or mock-infected with the medium only. After 66 h, cell viability was determined using either the neutral red method or the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). For the neutral red method, the cells were washed twice with PBS, and 100 μL of DMEM pH 4.5 containing 0.066% neutral red was added to the cells for 2 h at 37 °C. The cells were again washed twice with PBS, 100 μL of buffer solution (50% EtOH, 1% acetic acid) was added, and the OD was read at 540 nM after a 10 min incubation at 37 °C with shaking. Data are expressed as the percent of neutral red or luminescent signal in wells of compound-treated cells compared to the signal in wells of uninfected, compound-free cells. The 50% effective concentration (EC50) is calculated as the concentration of the compound that increases the percent of the neutral red or luminescent signal in infected, compound-treated cells to 50% of that produced by uninfected, compound-free cells. The 50% cytotoxicity concentration (CC50) is calculated as the concentration of the compound that decreases the percent of the neutral red or luminescent signal in uninfected, compound-treated cells to 50% of that produced in uninfected, compound-free cells.51,52"}

2_test

{"project":"2_test","denotations":[{"id":"33054210-3983963-61913462","span":{"begin":1634,"end":1636},"obj":"3983963"},{"id":"33054210-28359770-61913463","span":{"begin":1637,"end":1639},"obj":"28359770"}],"text":"All assays were performed in BSL3 containment. Vero 76 cells were plated at 10 000 cells per well using phenol red-free DMEM or IMEM (Gibco). After adhering for 2 h at 37 °C, various concentrations of compound (320, 100, 33, 10, 3.3, 1.0, 0.3, or 0.1 μM) were added and the cells were infected with 2.6 × 103 PFU/well SARS CoV Toronto-2 (provided as a gift from Dr. Heinz Feldman (NIAID, Hamilton, MT)) or mock-infected with the medium only. After 66 h, cell viability was determined using either the neutral red method or the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). For the neutral red method, the cells were washed twice with PBS, and 100 μL of DMEM pH 4.5 containing 0.066% neutral red was added to the cells for 2 h at 37 °C. The cells were again washed twice with PBS, 100 μL of buffer solution (50% EtOH, 1% acetic acid) was added, and the OD was read at 540 nM after a 10 min incubation at 37 °C with shaking. Data are expressed as the percent of neutral red or luminescent signal in wells of compound-treated cells compared to the signal in wells of uninfected, compound-free cells. The 50% effective concentration (EC50) is calculated as the concentration of the compound that increases the percent of the neutral red or luminescent signal in infected, compound-treated cells to 50% of that produced by uninfected, compound-free cells. The 50% cytotoxicity concentration (CC50) is calculated as the concentration of the compound that decreases the percent of the neutral red or luminescent signal in uninfected, compound-treated cells to 50% of that produced in uninfected, compound-free cells.51,52"}